GlassScriptPhysician profile
Angela Magdaleno
NPI 1720475189
$3,530.78
in general payments reported to CMS, 2019-2025
12 companies · $1,848 in 2025
The $1,848 reported for 2025 was more than what 75% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $840 · 2020: $85.37 · 2021: $157 · 2022: $178 · 2023: $144 · 2024: $279 · 2025: $1,848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,245 · Food and Beverage: $1,026.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,245.00 |
| Food and Beverage | $1,026.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $1,258.43 | 2025 | Rezdiffra |
| Novo Nordisk INC | $1,021.67 | 2019-2025 | Wegovy |
| Pfizer INC. | $750.00 | 2019 | |
| Lilly USA, LLC | $258.95 | 2024-2025 | Zepbound |
| Tandem Diabetes Care, INC. | $85.37 | 2020 | |
| Sanofi-Aventis U.S. LLC | $45.81 | 2021-2022 | |
| Abiomed | $29.53 | 2024 | Impella |
| Dexcom, INC. | $26.12 | 2025 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $17.70 | 2022 | |
| Abbott Laboratories | $13.20 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.87 | 2023 | Xarelto |
| Amgen INC. | $11.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Magdaleno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.